Candriam S.C.A. Biomarin Pharmaceutical Inc Transaction History

Candriam S.C.A.

$16.8 Billion
Q2 2025

A detailed history of Candriam S.C.A. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Candriam S.C.A. holds 549,655 shares of BMRN stock, worth $29 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

549,655

Previous 607,862 9.58%

Holding current value

$29 Million

Previous $43 Million 29.68%

% of portfolio

0.18%

Previous 0.28%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$54.08 - $68.32 $3.15 Million - $3.98 Million	-58,207 Reduced 9.58%	549,655 $30.2 Million
Q1 2025 May 14, 2025	BUY	$61.25 - $72.83 $1.69 Million - $2.01 Million	27,640 Added 4.76%	607,862 $43 Million
Q4 2024 Feb 06, 2025	BUY	$61.93 - $70.49 $15.7 Million - $17.8 Million	252,820 Added 77.22%	580,222 $38.1 Million
Q3 2024 Nov 13, 2024	SELL	$69.02 - $93.84 $13.6 Million - $18.6 Million	-197,736 Reduced 37.65%	327,402 $23 Million
Q2 2024 Aug 05, 2024	BUY	$74.43 - $92.22 $10.9 Million - $13.5 Million	146,827 Added 38.81%	525,138 $43.2 Million
Q1 2024 May 03, 2024	BUY	$83.81 - $99.0 $7.66 Million - $9.05 Million	91,383 Added 31.85%	378,311 $33 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $4.7 Million - $6.07 Million	-61,621 Reduced 17.68%	286,928 $27.7 Million
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $5.91 Million - $6.56 Million	-69,478 Reduced 16.62%	348,549 $30.8 Million
Q2 2023 Aug 08, 2023	SELL	$86.68 - $100.3 $11.9 Million - $13.8 Million	-137,428 Reduced 24.74%	418,027 $36.2 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $4.75 Million - $6.35 Million	54,144 Added 10.8%	555,455 $54 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $13.6 Million - $18.3 Million	168,416 Added 50.59%	501,311 $51.9 Million
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $4.83 Million - $5.69 Million	-58,735 Reduced 15.0%	332,895 $28.2 Million
Q2 2022 Aug 03, 2022	SELL	$71.48 - $86.85 $1.55 Million - $1.88 Million	-21,647 Reduced 5.24%	391,630 $32.5 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $10.3 Million - $12.9 Million	139,070 Added 50.72%	413,277 $31.9 Million
Q4 2021 Feb 10, 2022	SELL	$71.72 - $91.47 $143,440 - $182,940	-2,000 Reduced 0.72%	274,207 $24.2 Million
Q3 2021 Nov 09, 2021	BUY	$74.77 - $85.47 $12.6 Million - $14.4 Million	168,364 Added 156.12%	276,207 $21.3 Million
Q2 2021 Jul 20, 2021	SELL	$75.51 - $84.79 $18.9 Million - $21.2 Million	-250,187 Reduced 69.88%	107,843 $9 Million
Q4 2020 Jan 22, 2021	SELL	$72.61 - $90.2 $710,779 - $882,967	-9,789 Reduced 2.66%	358,030 $31.4 Million
Q3 2020 Oct 19, 2020	SELL	$71.87 - $131.03 $130,875 - $238,605	-1,821 Reduced 0.49%	367,819 $28 Million
Q2 2020 Jul 23, 2020	BUY	$79.55 - $124.22 $3.76 Million - $5.87 Million	47,225 Added 14.65%	369,640 $45.6 Million
Q4 2019 Jan 21, 2020	SELL	$64.27 - $86.37 $2.38 Million - $3.2 Million	-37,105 Reduced 10.32%	322,415 $27,000
Q3 2019 Oct 21, 2019	SELL	$67.4 - $85.11 $5.82 Million - $7.35 Million	-86,410 Reduced 19.38%	359,520 $24,000
Q2 2019 Aug 01, 2019	SELL	$80.35 - $93.9 $1.12 Million - $1.31 Million	-13,922 Reduced 3.03%	445,930 $38 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $4.48 Million - $5.92 Million	55,859 Added 13.83%	459,852 $39.2 Million
Q3 2018 Nov 07, 2018	BUY	$93.92 - $105.72 $13 Million - $14.7 Million	138,700 Added 52.28%	403,993 $39.2 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $4.22 Million - $5.5 Million	55,500 Added 26.45%	265,293 $25 Million
Q4 2017 Feb 07, 2018	SELL	$80.76 - $95.13 $1.88 Million - $2.21 Million	-23,244 Reduced 9.97%	209,793 $18.7 Million
Q3 2017 Nov 03, 2017	BUY	$80.6 - $94.95 $18.8 Million - $22.1 Million	233,037	233,037 $21.7 Million

Others Institutions Holding BMRN

# of Institutions

689

Shares Held

187M

Call Options Held

1.31M

Put Options Held

1.1M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $9.79B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account